University of London

London, England
Department of Neuroscience

Research

Children and adolescents who are cancer patients have only a few treatments specifically designed for their cancer. The lack of development of pediatric cancer drugs forces pediatric oncologists to use adult cancer drugs to treat their young patients. Dr. Cesare Spadoni, who lost his first daughter to cancer, is identifying treatments for the most common pediatric cancers with poorest prognoses. Two of the cancers at the forefront of his efforts are Medulloblastoma and Rhabdomyosarcoma.

Medulloblastoma accounts for 20% of all childhood brain tumors and has high heterogeneity and a tendency to metastasize. Ongoing research has identified 3 synergistic combinations that inhibit several targets found in the cancer and next steps with bioinformatics will identify a lead compound against two targets in vitro and in vivo models of medulloblastoma.

Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma with the aggressive subtype, alveolar rhabdomyosarcoma, resulting from fusion of two genes, PAX3 and FOXO1. In preclinical research, the small molecule drug, volasertib, which inhibits PLK1 enzyme, results in reduced expression of the abnormal fused proteins. Volasertib has already been studied as single agent in Phase I clinical trials in children with leukemia and refractory solid tumors and the recommended Phase 2 dose (RP2D) for children has been defined. The combined treatment of volasertib and chemotherapy vincristine may begin a Phase I clinical trial to treat relapsed or refractory rhabdomyosarcoma patients with and without the gene fusion abnormalities.

With NFCR support, Dr. Spadoni’s efforts have led to this promising therapeutic now being commercialized through the AIM-HI Translational Research Initiative. To learn more, click here.

Bio

Cesare Spadoni holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest. He has more than 20 years of experience in the drug development field, in both scientific and commercial roles. He started his career as research scientist in a pharmaceutical company (Eisai, London) and in academia (Institute of Enzymology, Budapest. He held senior positions at AMRI, Aptuit Laurus, ThalesNano and Auxiliis BV. After losing his first daughter to cancer, he founded the aPODD foundation, a London-based charity focused on accelerating pediatric oncology drug development for treating childhood cancer. As chairman and trustee, he is actively involved on a pro-bono basis in drug repurposing projects, advocacy efforts and research collaborations with other childhood cancer charities.

Related Content

Exercise Training May Slow Tumor Growth and Improve Immunotherapy Outcomes in Breast Cancer Treatment

Exercise plays an important role in preventing a variety of cancers. A recent study has increased the importance of maintaining a well-balanced and active lifestyle – indicating a positive outlook for many breast cancer patients.  National Foundation for Cancer Research (NFCR)-funded scientist Dr. Rakesh Jain, and his team at Massachusetts General Hospital and Harvard Medical School found that exercise training may slow tumor growth and improve outcomes for females with breast cancer – especially those treated with immunotherapy drugs. Immunotherapy drugs are treatments that use the body’s immune system to fight diseases like cancer. The research team identified this occurrence to be caused by stimulating naturally occurring immune mechanisms.   The team reached this conclusion in animal models of breast cancer, which showed physical activity increasing levels of cancer-fighting immune cells. Tumors in mouse models of human breast cancer grew more slowly in mice put through their paces in a structured aerobic exercise program than in sedentary mice. The tumors in exercised mice exhibited an increased anti-tumor immune response. Perhaps the most exciting finding of the study was that exercise training brought immune cells capable of killing cancer cells into tumors. The tumors grew more slowly in mice that performed exercise training. Dr. Jain has been an NFCR partner since 1998. He is a renowned world expert in understanding how changes in the microenvironment surrounding tumors affect the immune system, drug delivery, treatment efficacy, and patient survival–with additional expertise in chemical engineering. In addition to his fellowship with NFCR, Dr. Jain is an elected member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. He is the ninth person ever to be elected to all three U.S. National Academies. He is also a Fellow of the American Association for Cancer Research (AACR) Academy. Throughout his career, Dr. Jain has also been the recipient of numerous prestigious awards. Including the 2012 Science of Oncology Award from the American Society of Clinical Oncology and the 2016 National Medal of Science from the President of the United States, Barack Obama. He received the Medal of Science for developing new ways to manipulate tumors. Dr. Jain and his team at Massachusetts General Hospital and Harvard Medical School were able to complete this game-changing research utilizing funding from NFCR. NFCR is dedicated to providing scientists in the lab the funding they need to make game-changing discoveries in cancer treatments, detection, and ultimately, to discover a cure for all types of cancer.  Support innovative and life-saving research findings like the work of Dr. Jain with NFCR.   Additional Reads You May Enjoy: NFCR-Supported Researcher Leads Study Aiming to Understand Which Patients May Respond Best to Immunotherapy Immunotherapy: Fighting Cancer and More? Cancer Research Applied to Develop COVID-19 Treatment Strategies   Stay connected with the cancer community! Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

Research Highlight: Preventing Breast Cancer Brain Metastasis

National Foundation for Cancer Research funded researcher Dr. Daniel A Haber recently unearthed an exciting discovery that may add years to the lives of late-stage breast cancer patients. Dr. Haber is fascinated by understanding drug resistance on a deeper level by studying individual tumor cells in patients’ blood. In December 2020, Dr. Haber and his team shared their exciting findings on how brain metastasis, or the spread of cancer to the brain, may be prevented. Brain metastases occur in about 10% of all patients with cancer and in as many as a third of women with advanced metastatic breast cancer. Though experts have made great strides in suppressing the spread of cancer, there is still little known about the cellular pathways that enable cancer cells to selectively grow in the brain; that is, until Dr. Haber and his research team identified a signaling pathway which appeared significantly more active in brain metastases from breast cancer. “We were looking for what properties of some breast cancer cells made it possible for the cells to grow in the brain, which is a rare but often deadly complication of breast cancer,” Dr. Haber explained. “We weren’t sure what we would find. In a way that’s what makes the discovery process so exciting.” The research commenced approximately 10 years ago while investigating circulating tumor cells (CTCs). As their research progressed, the team homed in on a specific signaling pathway named HIF1A. Using cells from women with breast cancer, the team observed how these cells acted in animal models. It was discovered that if HIF1A was suppressed, the rate of proliferation (or rapid growth) was reduced. Simply put, blocking the HIF1A signaling pathway could reduce the rate of brain metastasis or even prevent it all together. “HIF1A is not specific to brain metastasis, since it’s a very broadly activated pathway in many cancers,” Dr. Haber began. “However, it appears to be more active in brain metastases from breast cancer than in primary breast cancers, and that may help explain what makes these metastases to the brain so unique and so difficult to treat.” The pathway identified in this research is already well known in the cancer world, however its special relevance to the brain was not known until now. Theoretically, a drug could be developed to suppress HIF1A and, in turn, prevent the spread of cancer. While a very promising discovery, Dr. Haber explains that there is far more work to be done. “There are a few HIF1A suppressing drugs now being tested in clinical trials for other indications,” Dr. Haber said, “However, we would have to expand this to multiple different models and systems before we could contemplate an intervention.” In regard to the length of time it takes to have a discovery such as this transitioned to mainstream treatment, Dr. Haber explains that it “depends on the discovery, its potential applications and some ‘luck’.” While the process from discovery to clinical treatment is getting faster all the time, it is likely going to take five to ten years before this finding is implemented into treatment. As for Dr. Haber, he has already planned plenty of work […]

The Forgotten Men of Breast Cancer

Breast Cancer Awareness Month, observed during October, presents many opportunities to acknowledge patients and survivors as well as opportunities to remind women to schedule their regular screening. The world lights up in pink, the color of the breast cancer ribbon, and shares messages of support to those affected. With 1 in 8 women estimated to be diagnosed with breast cancer at some point in her life, October reminds us all how important it is to self-examine one’s breasts as well as to schedule a mammogram. However, in the urgent messaging towards women, the men affected by breast cancer are often forgotten.  About Male Breast Cancer Breast cancer in men is rare, but it does affect approximately https://www.komen.org/breast-cancer/treatment/issues/male-breast-cancer/ in the United States each year. Though this only accounts for about 1% of all breast cancer diagnoses in the United States, it is important that men are aware of their risk of developing breast cancer. Many men, and women for that matter, are not aware that breast cancer affects both sexes. However, the truth is that all people are born with breast tissue making every individual susceptible to the disease. Of the men who develop breast cancer, the majority of the cases are infiltrating ductal carcinoma (IDC). IDC means that the cells in or around the ducts begin to invade the surrounding tissue. Breast Cancer Detection for Men Acknowledging that men can be diagnosed with breast cancer is the first step in protecting oneself from the disease. This knowledge allows men to pay attention to changes in the breast or nipple area and to speak to a doctor when identifying such changes. A common warning sign of breast cancer is a lump in the breast, chest, or underarm region. These lumps are often painless but should trigger men’s concern. Other early warning signs include dimpling or puckering of the skin, change in the size of the breast region, changes to the skin texture, an inverted nipple, or even discharge from the nipple. When men identify these warning signs and speak to a doctor, the likelihood of treating cancer at an early stage increases significantly. Treating cancer at an early stage gives all patients a higher chance of survival.  While all men should be monitoring their bodies for unusual changes, some specific men are at an increased risk of breast cancer. In general, men over 60 years old and those with a family history of cancer are at an increased risk for cancer. Overweight and obese men are also at an increased risk. Additionally, researchers have discovered that men with a specific gene mutation are more likely to develop breast cancer than those without it. The BRCA2 gene mutation is an inherited mutation and not only increases the likelihood of breast cancer but other cancers as well.  Throughout Breast Cancer Awareness Month, the public is made aware of the recommended screening processes for women concerning breast cancer. However, since breast cancer is quite rare amongst men, there are no recommended screenings for the average man. This makes it especially important for men to monitor their bodies for changes and speak to a doctor if they have any concerns. Those who have a family […]